+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer



Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer



Lung Cancer 16(2-3): 215-222



Patients with cardiac tamponade or large malignant pericardial effusion, who survived longer than 30 days after withdrawal of catheter from the pericardial space, entered the study. Main goal of investigations was: evaluation of the effectiveness and side-effects of intrapericardial administration of cisplatin in cases with malignant pericardial effusion (MPE) and cardiac tamponade or large pericardial effusion in a course of the lung cancer. Sixteen patients (four women and 12 men), mean age 53 years, median age 57 years, range 27-70 years, entered this retrospective study. After pericardiocentesis and insertion of a polyurethane catheter, pericardial fluid was drained. Malignant etiology of pericardial fluid was confirmed by cytological examination and/or by echocardiography. The diagnosis of malignancy was based upon histological examination of samples obtained from primary tumor. After confirmation of MPE cisplatin (10 mg in 20 ml normal saline) was instilled over 5 min during 1-5 consecutive days (maximal total cisplatin dose in single course: 50 mg) directly into pericardial space. If a large pericardial fluid reoccurred the courses with intrapericardial administration of cisplatin were repeated. Treatment was considered successful if the patient with malignant effusion survived 30 days without recurrence of symptoms of large pericardial effusion and no other interventions directed to the pericardium were required. In 14 (87.5%) cases malignant pericardial effusion was confirmed by cytological analysis of pericardial fluid. In two cases echocardiography confirmed metastatic tumors to the pericardium. Positive effect of intrapericardial treatment with cisplatin was achieved in 15 cases (93.75%). Mean survival period in the whole group was 6.59 months (+/-6.2 months), median survival period was 3.7 months, range 2-24.1 months. There were no complications related to the pericardiocentesis. Transient atrial fibrillation was detected in three patients (18.8%). Mild nausea occurred in one case. No hypotension and retrosternal pain were observed. Cisplatin administered directly into pericardial space (CAP) seems to be effective and safe. No sclerosis of the pericardial space was observed after CAP.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046455719

Download citation: RISBibTeXText

PMID: 9152952

DOI: 10.1016/S0169-5002(96)00631-9


Related references

Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion. Journal Of Cancer Research & Clinical Oncology. 120(7): 434-436, 1994

Intrapericardial infusion of etoposide and cisplatin in treating malignant pericardial effusion of non-small cell lung cancer. Ai Zheng 25(4): 505-508, 2006

Clinical observation on pericardial effusion in patients with lung cancer treated by intrapericardial catheterization and infusion of highly agglutinative staphylococcin and cisplatin. Chinese-German Journal of Clinical Oncology 5(5): 316-318, 2006

Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. British Journal of Cancer 83(7): 858-862, 2000

Intrapericardial cisplatin in malignant pericardial effusion. European Journal of Cancer 27(SUPPL 3): S57, 1991

Intrapericardial cisplatin combined with oral colchicine resulted in long term control of malignant pericardial effusion in the course of metastatic renal cancer. Advances in Respiratory Medicine, 2018

A case of advanced lung cancer with malignant pericardial effusion treated by intrapericardial Cinobufacini injection instillation. Bioscience Trends 8(4): 235-239, 2015

Successful treatment of intrapericardial administration of carboplatin in a case of squamous cell lung cancer with malignant pericardial effusion. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 18(13): 2337-2340, 1991

Intrapericardial mitomycin C for the management of malignant pericardial effusion secondary to gastric cancer: case report and review. ChemoTherapy 40(1): 57-60, 1994

Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Supportive Care in Cancer 12(1): 53-57, 2003

Evaluation of intrapericardial cisplatin administration in cases of recurrent malignant pericardial effusion and cardiac tamponade. Pneumonologia i Alergologia Polska 64 Suppl 2: 180-186, 1996

Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review. Oncotargets and Therapy 8: 2767-2770, 2015

Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget (): -, 2016

Intrapericardial interferon in the management of malignant pericardial effusion. Chest 114(1): 330-331, 1998

Intrapericardial ok 432 installation for the management of malignant pericardial effusion. Cancer 68(2): 259-263, 1991